{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:20:47Z","timestamp":1791663647154,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00296-015-3348-4","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T07:42:27Z","timestamp":1440661347000},"page":"143-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany"],"prefix":"10.1007","volume":"36","author":[{"given":"Ramon","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augstina","family":"Ogbonnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prina","family":"Donga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Makin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"issue":"9285","key":"3348_CR1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903\u2013911","journal-title":"Lancet"},{"key":"3348_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","volume":"7","author":"F Salaffi","year":"2009","unstructured":"Salaffi F, Carotti M, Gasparini S et al (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of health people. Health Qual Life Outcomes 7:25","journal-title":"Health Qual Life Outcomes"},{"key":"3348_CR3","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/ar3699","volume":"14","author":"G Berdal","year":"2012","unstructured":"Berdal G, Halvorsen S, Heijde D et al (2012) Restrictive pulmonary function is more prevalent in patients with ankylosing spondylitis than in matched population controls and is associated with impaired spinal mobility: a comparative study. Arthritis Res Therapy 14:R19","journal-title":"Arthritis Res Therapy"},{"key":"3348_CR4","unstructured":"NICE Technology Appraisal Guidance 143. Adalimumab, etanercept and infliximab for ankylosing spondylitis. http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA143Guidance.pdf . Accessed on 4 June 2013"},{"key":"3348_CR5","unstructured":"NICE Technology Appraisal Guidance 199. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. http:\/\/www.nice.org.uk\/nicemedia\/live\/13110\/50422\/50422.pdf . Accessed on 4 June 2013"},{"issue":"6","key":"3348_CR6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964\u2013975","journal-title":"Ann Rheum Dis"},{"key":"3348_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, Berg R, Boehm H et al (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896\u2013904","journal-title":"Ann Rheum Dis"},{"key":"3348_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C et al (2012) European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71:4\u201312","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3348_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26\u201337","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3348_CR10","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279\u20133289","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3348_CR11","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB et al (2012) Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64(8):2504\u20132517","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3348_CR12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48\u201355","journal-title":"Ann Rheum Dis"},{"issue":"9227","key":"3348_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385\u2013390","journal-title":"Lancet"},{"key":"3348_CR14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0950-3579(05)80305-X","volume":"9","author":"F Wolfe","year":"1995","unstructured":"Wolfe F (1995) The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 9:619\u2013632","journal-title":"Baillieres Clin Rheumatol"},{"issue":"10","key":"3348_CR15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CPP47617","volume":"47","author":"H Becher","year":"2009","unstructured":"Becher H, Kostev K, Schr\u00f6der-Bernhardi D (2009) Validity and representativeness of the \u201cDisease Analyzer\u201d patient database for use in pharmacoepidemiological andpharmacoeconomic studies. Int J Clin Pharmacol Ther 47(10):617\u2013626","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3348_CR16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/9781119959946.ch15","volume-title":"Pharmacoepidemiology","author":"A Ogdie","year":"2012","unstructured":"Ogdie A, Langan SM, Parkinson J, Dattani H, Kostev K, Gelfand JM (2012) Medical Record Databases. In: Strom BL, Kimmel SE, Hennessy S (eds) Pharmacoepidemiology, 5th edn. Wiley, Oxford, pp 224\u2013243","edition":"5"},{"issue":"5","key":"3348_CR17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.18553\/jmcp.2015.21.5.409","volume":"21","author":"F Buckley","year":"2015","unstructured":"Buckley F, Finckh A, Huizinga TW et al (2015) Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm. 21(5):409\u2013423","journal-title":"J Manag Care Spec Pharm."},{"issue":"1","key":"3348_CR18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jbspin.2013.05.001","volume":"81","author":"G Rajzbaum","year":"2014","unstructured":"Rajzbaum G, Grados F, Evans D et al (2014) Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European forsteo observational study. Joint Bone Spine. 81(1):69\u201375","journal-title":"Joint Bone Spine."},{"issue":"10","key":"3348_CR19","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1161\/STROKEAHA.107.487017","volume":"38","author":"F Colivicchi","year":"2007","unstructured":"Colivicchi F, Bassi A, Santini M et al (2007) Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38(10):2652\u20132657","journal-title":"Stroke"},{"issue":"2","key":"3348_CR20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/eurheartj\/ehl391","volume":"28","author":"FJ Penning-van Beest","year":"2007","unstructured":"Penning-van Beest FJ, Termorshuizen F, Goettsch WG et al (2007) Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40 %: a cohort study. Eur Heart J 28(2):154\u2013159","journal-title":"Eur Heart J"},{"issue":"3","key":"3348_CR21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516\u2013528","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3348_CR22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CEOR.S66338","volume":"18","author":"L Degli Esposti","year":"2014","unstructured":"Degli Esposti L, Sangiorgi D, Perrone V, Radice S, Clementi E, Perone F, Buda S (2014) Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. Clinicoecon Outcomes Res. 18(6):401\u2013407","journal-title":"Clinicoecon Outcomes Res."},{"key":"3348_CR23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.20419","volume":"51","author":"SM Verstappen","year":"2004","unstructured":"Verstappen SM, Bijlsma JW, Verkleij H et al (2004) Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 51:488\u2013497","journal-title":"Arthritis Rheum"},{"key":"3348_CR24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/rheumatology\/39.1.28","volume":"39","author":"NJ Cooper","year":"2000","unstructured":"Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39:28\u201333","journal-title":"Rheumatology (Oxford)"},{"issue":"14","key":"3348_CR25","first-page":"1","volume":"15","author":"K Mulottki","year":"2011","unstructured":"Mulottki K, Barton P, Tsourapas A et al. (2011) Adalimumab, etanercept, infliximab, rituximab, and abatacept for the tratement of rheumatoid arthritis aftterfailure of a tumor necrosiss factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 15(14):1\u2013278","journal-title":"Health Technol Assess"},{"issue":"3","key":"3348_CR26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2217\/ijr.10.15","volume":"5","author":"S Sofia De Achaval","year":"2010","unstructured":"Sofia De Achaval S, Suarez-Almazor ME (2010) Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol. 5(3):313\u2013326","journal-title":"Int J Clin Rheumtol."},{"issue":"14","key":"3348_CR27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460\u20131468","journal-title":"JAMA"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3348-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-015-3348-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3348-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:28:32Z","timestamp":1559028512000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-015-3348-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3348"],"URL":"https:\/\/doi.org\/10.1007\/s00296-015-3348-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]}}}